Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical^® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

“We are excited about expanding the clinical indications for Magneceutical® Therapy, and pleased to have Dr. Trevino coordinating our pilot study to establish the clinical potential of Magneceutical® Therapy for fibromyalgia patients”

The study will be coordinated by Miguel Trevino, M.D., Medical Director, Innovative Research of West Florida, Clearwater, Fla. Dr. Trevino is certified to practice medicine by the American Board of Internal Medicine. Innovative Research of West Florida is a leading Clinical Research Site.

"We are excited about expanding the clinical indications for Magneceutical® Therapy, and pleased to have Dr. Trevino coordinating our pilot study to establish the clinical potential of Magneceutical® Therapy for fibromyalgia patients," said Allen Braswell, CEO of Pico-Tesla.

Fibromyalgia (pronounced fy-bro-my-AL-ja) is a common and complex chronic pain disorder that affects people physically, mentally and socially. Fibromyalgia, which has also been referred to as fibromyalgia syndrome, fibromyositis and fibrositis, is characterized by chronic widespread pain, multiple tender points, abnormal pain processing, sleep disturbances, fatigue and often psychological distress. For those with severe symptoms, fibromyalgia can be extremely debilitating and interfere with basic daily activities. (Source: National Fibromyalgia Association)

Pico-Tesla's Magneceutical^® Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—intended to improve a number of the signs and symptoms of fibromyalgia and other disorders and diseases, including atrial fibrillation, Parkinson's disease, Alzheimer's disease and osteoarthritis.